Epratuzumab
- Generic Name
- Epratuzumab
- Drug Type
- Biotech
- CAS Number
- 205923-57-5
- Unique Ingredient Identifier
- 3062P60MH9
- Background
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
- Indication
Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 700
- Registration Number
- NCT01802814
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇦🇹St. Anna Kinderkrebsforschung, CCRI, Vienna, Austria
🇦🇺Australian & New Zealand Childhood Hematology & Oncology Group, Clayton, Victoria, Australia
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1250
- Registration Number
- NCT01408576
- Locations
- 🇺🇸
053, New York, New York, United States
🇮🇱381, Jerusalem, Israel
🇷🇺285, Petrozavodsk, Russian Federation
Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT01354457
- Locations
- 🇫🇷
CHU Nantes, Nantes, France
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 793
- Registration Number
- NCT01262365
- Locations
- 🇧🇷
455, Campinas, Brazil
🇺🇸031, Los Angeles, California, United States
🇺🇸040, Baltimore, Maryland, United States
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 791
- Registration Number
- NCT01261793
- Locations
- 🇭🇺
715, Szeged, Hungary
🇮🇹648, Milano, Italy
🇮🇹646, Roma, Italy
Multi-centric Study
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT01219816
- Locations
- 🇫🇷
Purpan Hospital, Toulouse, France
🇫🇷Nantes University Hospital, Nantes, France
🇫🇷CHU de Poitiers, Poitiers, France
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- LeukemiaPediatric Cancer
- Interventions
- Procedure: Infusion of NK cells
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00941928
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
- Conditions
- Lymphoma, Non-HodgkinLymphomas: Non-HodgkinLymphomas: Non-Hodgkin Cutaneous LymphomaLymphomas: Non-Hodgkin Diffuse Large B-CellLymphomas: Non-Hodgkin Follicular / Indolent B-CellLymphomas: Non-Hodgkin Mantle CellLymphomas: Non-Hodgkin Marginal ZoneLymphomas: Non-Hodgkin Peripheral T-CellLymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 500
- Registration Number
- NCT00398372
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 54
- Registration Number
- NCT00383214
Study of Epratuzumab in Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00382837
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.